Overview

Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Application of Topical BioLexa in Adult Healthy Subjects and Patients With Mild to Moderate Atopic Dermatitis

Status:
Recruiting

Trial end date:
2022-02-28

Target enrollment:

Participant gender:

Summary

This is a Phase 1, randomised, double-blind, vehicle controlled study to determine the safety, tolerability, PK and efficacy of twice daily application of topical BioLexa™ lotion, administered for 28 days in adult healthy subjects, in adult patients with mild to moderate AD and in adolescent patients with mild to moderate AD.

Phase:

Phase 1

Details

Lead Sponsor:

Hoth Therapeutics, Inc.

Collaborator:

Novotech (Australia) Pty Limited

Treatments:

Gentamicins